S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Enanta Pharmaceuticals, Inc

ENTA XNAS
$13.77 +0.43 (+3.22%) ▲ 15-min delayed
Open
$13.43
High
$13.87
Low
$13.35
Volume
183.0K
Market Cap
$387.91M

About Enanta Pharmaceuticals, Inc

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 120 Website →

Key Financials

Period Revenue Net Income EPS
Q2 2026 $17.16M $-13,091,000 $-0.45
Q1 2026 $18.61M $-11,938,000 $-0.42
FY 2025 $65.32M $-81,889,000 $-3.84
Q2 2025 $14.93M $-22,644,000 $-1.06

Related Market News

No specific coverage for ENTA yet. Check out our latest market news or earnings calendar.

Get ENTA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Enanta Pharmaceuticals, Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.